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Abstract
Background: There are limited long-term randomized controlled trials of growth hormone (GH) supplementation
to adult height and few published reports of the health-related quality of life (HRQOL) following treatment. The
present follow-up study of young adults from a long-term controlled trial of GH treatment in patients with Turner
syndrome (TS) yielded data to examine whether GH supplementation resulted in a higher HRQOL (either due to
taller stature or from the knowledge that active treatment and not placebo had been received) or alternatively a
lower HRQOL (due to medicalization from years of injections).
Methods: The original trial randomized 154 Canadian girls with TS aged 7-13 years from 13 centres to receive
either long-term GH injections at the pharmacologic dose of 0.3 mg/kg/week or to receive no injections; estrogen
prescription for induction of puberty was standardized. Patients were eligible for the follow-up study if they were
at least 16 years old at the time of follow-up. The instrument used to study HRQOL was the SF-36, summarized
into physical and mental component scales (PCS and MCS); higher scores indicate better HRQOL.
Results: Thirty-four of the 48 eligible participants (71%) consented to participate; data were missing for one patient. Both
groups (GH and no treatment) had normal HRQOL at this post-treatment assessment. The GH group had a (mean ± SD)
PCS score of 56 ± 5; the untreated group 58 ± 4; mean score for 16-24 year old females in the general population 53.5 ±
6.9. The GH group had a mean MCS score of 52 ± 6; the untreated group 49 ± 13; mean score for 16-24 year old females
in the general population 49.6 ± 9.8. Secondary analyses showed no relationship between HRQOL and height.
Conclusions: We found no benefit or adverse effect on HRQOL either from receiving or not receiving growth
hormone injections in a long-term randomized controlled trial, confirming larger observational studies. We suggest
that it remains ethically acceptable as well as necessary to maintain a long-term untreated control group to
estimate the effects of pharmacological agents to manipulate adult height. Young adult women with TS have
normal HRQOL suggesting that they adjust well to their challenges in life.
Trial Registration: ClinicalTrials.gov Identifier NCT00191113.
Background
Growth hormone supplementation of short children with-
out growth hormone deficiency is increasing worldwide.
However, long-term randomized trials that remain con-
trolled until adult height has been reached are rare, as are
published follow-up data on the quality of life of the parti-
cipants [1]. We previously identified several barriers to
such long-term trials including physician discomfort with
random assignment of children to an untreated long-term
control group [1]. However, two long-term randomized
controlled trials of growth hormone supplementation [2,3]
have been conducted in girls with Turner syndrome [4], a
population in whom growth hormone supplementation is
widely used [5].
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A recent literature search (details not shown) on the
health-related quality of life in young adults with Turner
syndrome who received growth hormone revealed no pub-
lished randomized controlled trials but yielded two obser-
vational studies that used the SF-36, a widely used, short,
generic, psychometrically sound measure of subjective
health status [6]. Carel et al surveyed 568 adult women
from a mandatory population-based treatment registry,
mean age 22.6 years, mean height 150.9 cm, 69% response
rate [7]. There were no effects of height or estimated
height gain from treatment on health-related quality of
life. Bannink et al surveyed 49 adult women who had been
treated with growth hormone in previous treatment stu-
dies, mean age 19.6 years; mean height 160.7 cm [8]. The
group had normal health-related quality of life, although
estimated height gain was positively correlated to one sub-
scale: “role limitations due to physical health problems”.
Earlier, Busschbach et al surveyed twenty-five short adult
women with Turner syndrome not treated with growth
hormone who were the first to respond to their request to
participate [9]. They found normal scores on the six
dimensions of the Nottingham Health Profile, an earlier
measure of health-related quality of life. They also found
that 68% would like to be taller and 44% were willing to
trade-off a small proportion of their total lifespan to that
end. Of the latter sub-group, the mean time trade-off in
exchange for normalization of height to the general popu-
lation average was 4.2% of lifespan, smaller than the total
group’s trade-off for not having infertility, 9% of lifespan.
Boman et al also used the Nottingham Health Profile in
relatively older women with Turner syndrome, mean age
37 years [10]. They reported significantly lower scores in
only one dimension, social isolation. Effects of height or
treatment with growth hormone were not reported.
Finally, Naess et al surveyed 80 relatively older women
with Turner syndrome, mean age 34 years; mean height
152.8 cm, 50% response rate from one specialty clinic and
one voluntary registry [11]. They reported significantly
lower scores in two SF-36 subscales: “physical functioning”
and “general health”. Associations of height or treatment
with growth hormone with SF-36 scores were not
reported. They suggested these significant findings may be
related to the older age at testing compared with the other
studies using the SF-36.
We performed a follow-up study of one of the two ran-
domized controlled trials [2] and included the collection
of health-related quality of life data on these young
women. The unblinded design of the trial allowed us to
not only test health-related quality of life hypotheses about
treatment outcomes but also treatment group assignment
effects. Specifically, we examined whether growth hor-
mone supplementation resulted in a higher health-related
quality of life (either due to taller stature or from the
knowledge that active treatment and not placebo had been
received) or alternatively a lower health-related quality
of life (due to medicalization owing to the years of
injections).
Methods
The original trial (ClinicalTrials.gov identifier
NCT00191113) randomized 154 Canadian girls with
Turner syndrome aged 7-13 years from 13 centers, using
centralized randomization, to receive either long-term
growth hormone injections at the pharmacologic dose of
0.3 mg/kg/week divided into six injections per week or to
receive no injections [2]. The participants were therefore
not blinded to treatment assignment but were otherwise
treated similarly. Owing to the high frequency of ovarian
failure in Turner syndrome, their treatment included a
standardized prescription for induction of puberty with
daily low dose estrogen (0.0025 mg ethinyl estradiol) after
reaching both a chronologic age of 13 years and a mini-
mum treatment with growth hormone of one year if in the
treated group. After one year of initial estrogen treatment,
this dose was increased to 0.005 mg for one additional
year before cyclic estrogen and progesterone replacement
was instituted. The primary results of the original trial
were that growth hormone supplementation increased
adult height in women with Turner Syndrome by 7.2 cm
on average (95% CI 6.0 - 8.4 cm) with high individual
variability in the magnitude of response.
The present study was conducted at six of the original
thirteen centers from October 1999–February 2001. The
predominant reason for non-participation of seven centers
was lack of clinician-investigator time or resources to ded-
icate to a multicenter project at that time. Participants
were eligible if they were at least 16 years of age within the
study window and had participated in the original study at
one of the six participating centers. The present study
received institutional research ethics board approval initi-
ally from the University of Manitoba Research Ethics
Board and subsequently from the ethics committee at
each of the other participating sites. Written informed
consent was obtained for each participant.
The SF-36 was used to measure health-related quality of
life [6]. Its 36 questions cover eight different health con-
cepts: physical functioning, role limitations due to physical
problems, bodily pain, general health, vitality, social func-
tioning, role limitations due to emotional problems, and
mental health. These eight concepts can be validly sum-
marized into two component scales: physical (PCS) and
mental (MCS) as long as findings specific to one of the
eight health concepts are not obscured [12]. The PCS and
MCS are expressed as norm-based scores with a popula-
tion mean of 50, and standard deviation of 10; higher
scores indicating better health. The instrument was admi-
nistered, in English or French, as a questionnaire for self-
completion prior to the remainder of the detailed
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questionnaire on participant demographics, medical his-
tory, risk factors for osteoporosis and auxologic and bone
densitometry measurements (to be published separately).
The SF-36 data were scored electronically by the Quality-
Metric scoring service (QualityMetric Inc., RI).
Continuous variables were summarized by mean and
95% confidence interval (CI) and categorical variables by
frequencies and 95% CIs. Bivariate comparisons were also
computed. The SAS (SAS Institute, NC) multiple linear
regression procedure, PROC REG, was used to regress the
SF-36 outcomes data on treatment assignment, adult
height, body mass index, and spontaneous menarche to
compute regression coefficients and their 95% CI. In addi-
tion to the intent-to-treat analysis, a planned sensitivity
analysis was run using the participants’ “as-treated” status;
post-hoc exploratory analyses were also done.
Results
Thirty-four of the 48 eligible participants (71%) consented
to participate in the present follow-up study; however data
were missing for one patient. The 21 participants rando-
mized to growth hormone were 20.0 years of age (SD 2.4),
148.9 cm tall (SD 5.7) and had a body mass index of 25.7
kg/m2 (SD 4.9); 19 were adherent to growth hormone
treatment long-term. The 12 participants randomized to
no injections were 20.2 years of age (SD 2.1), 143.7 cm tall
(SD 6.1) and had a body mass index of 24.2 (SD 3.7); 10 of
the 12 had never received growth hormone injections.
Both study groups had a normal health-related quality of
life similar to the norms for females aged 18-24 years from
the general Canadian population [13]; treatment group:
PCS 56 (SD 4.9), MCS 52 (SD 6.3) and control group: PCS
58 (SD 4.2), MCS 49 (SD 13.2) (see Table 1). The indivi-
dual subscales were also normal for both groups.
Separating the 33 patients by adult height revealed no
association with SF-36 score. The 13 patients who were
taller than the average (mean height 153.6 cm, SD 3.9) had
a PCS of 56.6 (SD 2.6), and a MCS of 52.3 (SD 5.1), while
the 20 patients shorter than the average (mean height
142.8 cm, SD 2.9) had a PCS of 56.9 (SD 5.7), and a MCS
of 50.1 (SD 11.4). Secondary multivariate analyses also
showed no statistically significant variables when regres-
sing either the PCS or MCS on age, body mass index, pre-
sence of spontaneous menarche, or growth hormone trial
treatment group. For the latter variable, growth hormone
trial treatment group, the mean effect on MCS was 4.6
points: 95% CI -2.7–12 and on PCS, -2.3 points; 95% CI
-5.9–1.3.
Discussion
Health-related quality of life is an increasingly popular
outcome as it subjectively measures how individuals feel
rather than what the objective outcomes imply they
ought to feel [6]. The similarity in scores between the
groups suggests that, for girls with Turner syndrome, the
impact of short stature and its treatment on health-
related quality of life as young adults may have been
overemphasized. It should be noted that the SF-36 is a
generic health-related quality of life instrument that
therefore may be unable to detect specific effects on
quality of life due to height differences that do not affect
the global physical or mental scores. Although our study
sample was small, the groups we studied were formed by
randomization and support the lack of a relationship of
adult height to PCS or MCS seen in a larger observa-
tional study [7]. However, a sample size of 64 experimen-
tal participants would have been required to exclude a
five point change on PCS or MCS under standard
Table 1 Participant characteristics and HR-QOL results
Randomized to growth hormone injections until adult height Randomized to no injections
Number 21 12
Age (years) 20.0 (SD 2.4) 20.2 (SD 2.1)
Height (cm) 148.9 (SD 5.7) 143.7 (SD 6.1)
BMI (kg/m2) 25.7 (SD 4.9) 24.2 (SD 3.7)
Adherence 20 received injections 10 did not receive growth hormone injections
SF-36 PCS 56 (SD 4.9) 58 (SD 4.2)
SF-36 MCS 52 (SD 6.3) 49 (SD 13.2)
SF-36 subscales with norms
Physical Functioning 54 (SD 5.9) 55 (SD 2.7)
Role Physical 56 (SD not calculable) 55 (SD 2.8)
Bodily Pain 58 (SD 5.4) 59 (SD 4.7)
General Health 53 (SD 6.4) 56 (SD 6.9)
Vitality 56 (SD 7.3) 55 (SD 7.8)
Social Functioning 53 (SD 7.5) 51 (SD 9.9)
Role Emotional 54 (SD 5.0) 49 (SD 11)
Mental Health 52 (SD 5.7) 50 (SD 11)
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assumptions: two-sided test, alpha = 0.05, 80% power
[12]. Calculating the effect size and 95% confidence inter-
val of growth hormone trial group using an analysis of
variance revealed that we have excluded a meaningful
clinical effect of growth hormone treatment on PCS but
not MCS. We do have limited data on the similarity of
participants to non-participants; specifically the adult
height data for our participants by treatment group,
148.9 cm versus 143.7 cm, are very similar to the adult
height results one year after protocol completion for the
parent trial, 149.0 cm versus 142.2 cm [2].
Conclusions
We found no benefit or adverse effect on health-related
quality of life in young adult women with Turner syn-
drome either from receiving or not receiving growth
hormone injections in a long-term randomized con-
trolled trial. However, we lacked the power to defini-
tively exclude a clinically relevant benefit of growth
hormone on MCS or a clinically relevant harm on PCS.
We suggest that it remains ethically acceptable as well
as necessary to maintain a long-term untreated control
group to estimate the effects of pharmacological agents
to manipulate adult height. This would apply equally to
new agents and to new adult height indications for
existing agents.
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